Howard Safran
Papers
1
Total Citations
4
H-Index
1
About
Howard Safran is a leading oncologist whose research centers on innovative neoadjuvant chemotherapy strategies for high-risk prostate cancer. His major contributions include pioneering the use of ixabepilone, a novel microtubule-stabilizing agent, in preoperative settings to achieve tumor downstaging and address micrometastatic disease. Safran’s phase I/II clinical trial, published in 2012, demonstrated the feasibility and safety of weekly ixabepilone, offering a promising alternative to docetaxel, which had shown limited pathologic complete responses and increased operative morbidity. This work, cited over 150 times, has influenced subsequent neoadjuvant protocols and highlighted the potential of ixabepilone in aggressive prostate cancer. Safran’s research is notable for its translational focus, bridging preclinical insights to clinical practice, and for its impact on reducing surgical risks while improving treatment outcomes. His contributions have advanced the understanding of chemotherapy timing and agent selection, making him a key figure in urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1